stockportfolio.pro
Stocks / COLL vs ZBIO
COLL vs ZBIO
Collegium Pharmaceutical, Inc. and Zenas BioPharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Collegium Pharmaceutical, Inc. (COLL) | Zenas BioPharma, Inc. (ZBIO) | |
|---|---|---|
| Market cap | $1.1B | $1.1B |
| Revenue (latest FY) | $780.57M | $10.00M |
| Net income (latest FY) | $62.87M | $-377.74M |
| Revenue growth (5y CAGR) | 20.3% | — |
| Net margin | 8.1% | -3777.4% |
| Return on equity | 20.8% | -156.0% |
| P/E ratio | 16.8 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open COLL — free Open ZBIO — freeFrequently asked questions
Which is bigger, COLL or ZBIO?
Zenas BioPharma, Inc. is larger by market capitalization — $1.1B versus $1.1B.
Which grows faster, COLL or ZBIO?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.